IDC 003
Alternative Names: IDC-003Latest Information Update: 07 Jun 2022
Price :
$50 *
At a glance
- Originator Prestige BioPharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CTHRC1 protein modulators; Immune checkpoint protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 06 May 2022 Prestige BioPharma plans a clinical trial (phase I-phase III) for solid tumours during the period 2024-2026
- 05 May 2022 Early research in Solid tumours in Singapore (Parenteral) (Prestige BioPharma pipeline, May 2022)
- 05 May 2022 Prestige BioPharma plans regulatory submission to EMA and US FDA for solid tumours in 2026